Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 21, 2026

Zacks Industry Outlook Highlights Applied Materials, Lam Research and FormFactor

View original at finance.yahoo.com
Zacks Industry Outlook Highlights Applied Materials, Lam Research and FormFactor For Immediate Release Chicago, IL – July 21, 2026 – Today, Zacks Equity Research discusses Applied Materials AMAT, Lam Research LRCX and FormFactor FORM…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The semiconductor industry is suffering from supply chain constraints and increasing manufacturing costs related to advanced packaging and larger HBM stacks.

    60% confidence
  • AI is increasing investments across leading-edge logic, DRAM, NAND, High-Bandwidth Memory (HBM) and advanced packaging rather than being concentrated in a single chip category.

    60% confidence
  • AI demand is expanding beyond model training into inference, agentic AI and eventually physical AI, creating sustained demand for advanced semiconductors.

    60% confidence
  • Tariffs on trade partners, including China, are expected to hurt the semiconductor industry's prospects.

    60% confidence
  • Increasing demand for AI-supportive chips from hyperscalers is a major growth driver for the semiconductor industry.

    60% confidence
  • The semiconductor industry is experiencing solid demand for advanced electronic equipment, helping participants increase investments in cost-effective process technologies.

    60% confidence
  • Industry participants are benefiting from growing demand for advanced manufacturing processes and energy-efficient computing power needed to develop AI-supportive chips.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Zacks Industry Outlook Highlights Applied Materials, Lam Research and FormFactor — Source | Via News | ViaNews Market